MEDBOT-B (02252) surged over 5%, rising 5.01% to HK$30.2 with trading volume of HK$130 million as of press time. On the news front, MEDBOT-B announced on October 8th that according to preliminary internal statistics, as of the announcement date, the cumulative comprehensive order volume for the group's core products in laparoscopy, orthopedics, and vascular intervention has exceeded 170 units. Among these, the core product TouMai laparoscopic surgical robot (TouMai) has accumulated over 100 commercial orders globally, with nearly 80 TouMai units installed worldwide, securing the leading position among domestic brands and entering a full acceleration phase of commercialization.

As the first domestic laparoscopic surgical robot to enter overseas markets, TouMai's overseas orders have exceeded 60 units, with installations covering nearly 40 countries and regions across Asia, Europe, Africa, Oceania, and South America. Large-scale clinical surgeries have been conducted in mainstream hospital systems across dozens of countries including Italy, Belgium, India, Brazil, Argentina, and the UAE.

Recently, the group achieved another milestone breakthrough in its commercial deployment in the global high-end medical market. TouMai successfully completed commercial deployment of both single-port and multi-port series at one of the world's top two medical institutions, successfully implementing a comprehensive intelligent surgical solution.